Passionate about our work, inspired by what it can do
ANNAIDA was founded in 2018 by Marco and Gora – two friends bound by a shared passion for physics, microtechnology, and life sciences. The name stands for Anna and Ida – their two Italian grandmothers. They invented the MRS device using the microchip developed during their Ph.D. studies in Switzerland – at EPFL in Lausanne and the University of Fribourg.
Annaida’s vision is to revolutionize how we measure, analyze and understand microscopic life using precise and non-invasive methods. MRS will create new opportunities for improvement of clinical outcomes, drug development, and scientific discovery. Annaida will continue investing resources and building knowledge to make the measurement and analysis of microscopic life easy, fast, and insightful.
Marco Grisi, PhD
CTO & co-founder
Marco pushes forward core technology and oversees development and research of Annaida. He co-founded Annaida after graduating, from the Swiss Federal Institute of Technology (EPFL) with a PhD in microengineering and microelectronics for NMR, because he recognizes the potential micro NMR technologies hold for the future.
Gora Conley, PhD
CEO & co-founder
Gora is responsible for driving public exposure efforts for Annaida. He obtained his PhD at the University of Fribourg (Switzerland), developing optical methods for synthetic and biological nanomaterials with a focus on project management and business development. After graduating, he co-founded Annaida with his lifelong friend Marco who shares his belief in the potential of micro NMR technologies.
Kathryn Marable, PhD
Kathryn is our R&D engineer, she is responsible for designing, constructing and testing the supporting electronics & mechanics on top of validating the performance of microchip sensors. Before joining Annaida, she completed a Ph.D. in experimental physics at Harvard University where she designed and constructed a cryogenic, radiofrequency antiproton trap in a strong magnetic field as part of the ATRAP collaboration at CERN.
Giulia Sivelli, PHD
Giulia is our embryologist and R&D scientist, she is responsible for lab management, cell cultures, experimental design and data analysis. Giulia has a Master of Science in Molecular Biology of the Cell and a PhD from the Royal Veterinary College (London, UK) where she studied mesenchymal stem cells driven tissue regeneration. She has also completed a master course in human assisted reproductive techniques from Pompeu Fabra University in collaboration with EUGIN clinics (Barcelona, Spain).
Guillaume is one of our R&D engineers. He participates in the development of our electronic test equipments and in the industrial design of EmbryoSpin. He has a Master of Science in Microengineering from EPFL (Lausanne, Switzerland) and a Minor in Energy.
Fabien Murisier, PhD
Dr. Mursier is a senior clinical embryologist at ESHRE (European Society of Human Reproduction and Embryology). He is also the head of the Fertility sector at the Medisupport group, member of the CPMA management board and chief executive officer of the Fertas laboratory. Fabien oversees early stage development of new IVF technologies, all the way to clinical trials and commercialization. He received his PhD from the University of Lausanne before joining the Human Genetics Unit of the MRC in Edinburgh.
Prof. Kurt Wüthrich
Kurt Wüthrich is a Professor of Biophysics at the ETH Zürich, and Distinguished Senior Professor at the iHuman Institute, ShanghaiTech University. For 50 years, Wüthrich groups at the ETH Zürich, at Scripps Research and at the iHuman Institute have used nuclear magnetic resonance spectroscopy (NMR) for research in structural biology. Contributions include the method of protein structure determination with NMR in solution, and the use of the principles of transverse relaxation-optimized spectroscopy (TROSY) for NMR experiments with large supramolecular assemblies. Kurt Wüthrich’s achievements in the sciences have been recognized by the Prix Louis Jeantet de Médecine, the Kyoto Prize in Advanced Technology, the Nobel Prize in Chemistry, and by a number of other awards and honorary degrees.
Riccardo Tediosi, PhD
Dr. Tediosi is a senior executive with a strong background in instrument development and in startup-scaleup ventures. He holds an executive MBA from IMD Business school and combines technical management background with sound business management practices. He is currently CTO at QualySense AG developing AI-based robotic platforms for contactless characterization of seeds. He has been R&D director at Bruker Biospin for the development of NMR/MRI probeheads for high-end MR systems. He holds a PhD in Solid State Physics at the University of Geneva after obtaining his Master degree in Photonics in Pavia.
Prof. Barry Behr
Prof. Barry Behr is a nationally and internationally renowned clinical and scientific leader in the research and advances of human reproduction. As a world-renown scientist and lecturer, he is highly sought after to chair scientific programs and conferences and is the first non MD President of the Pacific Coast Reproductive Society to be appointed as program chairman of several professional meetings. He is the director of the IVF/ART laboratory at Stanford University and is the Faculty Advisor for the Transgenic, Knockout and Tumor Model Center. In the 90’s Dr. Behr developed a culture medium for embryo culture to the blastocyst stage, which has improved pregnancy rates, implantation rates and reduced the risks of multiple gestation in IVF. He is also the co-inventor of an embryo selection technology that was featured in Time Magazine’s Best of Everything as 8th place in the top 10 Medical Breakthroughs of 2010.
Board of Directors
Pascal is a co-founder and the CEO of HEMEX, a pharmaceutical, biotech and medical device consulting firm with offices in Switzerland, Germany and the USA. Previously he worked for Finox Biotech, bringing one of the first biosimilar fertility treatments to the market in the EU and leading to the successful acquisition by Gedeon Richter for EUR 190 million in 2016.
Jacqueline Ruedin Rüsch
Jacqueline Ruedin Rüsch started her entrepreneurial career in 2011 when she founded Privilège Management SA. She started to focus her investment activity in venture capital shortly after and launched the first VC fund in 2016. Since then, she has invested in over 30 companies and prides herself in having a very hands-on approach. She is a board member in a number of companies and her professional activity has led her to co-found Privilège Ventures SA, a venture capital firm based in Lugano.
ANNAIDA is pioneering a new non-invasive technology to investigate the chemistry inside microscopic life while maintaining its full integrity. We are dedicated to analysing cellular life and better understanding its metabolic fingerprint. The unprecedented scale of our device allows for a precise understanding of cells ranging from embryos to stem-cell organoids and much more.
ANNAIDA’s Quality Policy is focused on the pursuit of Customer and Interested Parties satisfaction, trust, and loyalty, as well as on full compliance with mandatory regulations/laws. It considers the internal and external context in which the Company operates, monitoring its performance and drawing inspiration from it for the definition of objectives, for continuous improvement and risk assessment in the process’s execution.
To make this possible, the Quality Policy Annaida has established, documented, implemented, maintained, and continually improves, in accordance with the requirements of ISO 9001:2015, specifically addresses all internal and external activities, and business, necessary to ensure Annaida’s success, focusing on the following aspects:
1. Customer Focus: Our first priority is to understand the needs and expectations of our customers and to meet or exceed them. We continuously strive to improve our customer satisfaction by providing quality products and services that meet their requirements.
2. Leadership: Our senior management is committed to the implementation and improvement of our QMS, and they lead by example in promoting quality as a fundamental aspect of our business activities.
3. Engagement of People: We recognize the importance of our employees in achieving our quality objectives and strive to provide a supportive and inclusive work environment that promotes individual growth and development.
4. Process Approach: We believe that processes are essential to the achievement of our quality objectives and we use a process approach to plan, design, implement, and improve our processes.
5. Continual Improvement: We are committed to continually improving our QMS and our products and services. We establish quality objectives and review our performance to determine areas for improvement.
6. Evidence-based Decision Making: We use data and information from our QMS to make informed decisions that enhance our ability to achieve our quality objectives.
7. Relationship Management: We strive to establish and maintain positive relationships with our suppliers, customers, and other stakeholders, recognizing that their success is key to our success.
We believe that a strong Quality Management System plays a significant role in helping us to achieve our ambitions, ensuring that ANNAIDA develop its place as leading worldwide company.
This policy is communicated, understood, and followed by all employees and is reviewed for continued suitability at least annually, during the management review.